Evidence map›Paper›PMID 25867259›Full record

ArticleBritish journal of cancer2015

Cytokine profiling of docetaxel-resistant castration-resistant prostate cancer.

K L Mahon, H-M Lin, L Castillo, B Y Lee, M Lee-Ng, M D Chatfield, K Chiam, S N Breit, D A Brown, M P Molloy and 7 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed
3.4field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 53 citations in OpenAlex.

  1. Trial
  2. Review
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Alterations of tumor microenvironment by nitric oxide impedes castration-resistant prostate cancer growth.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  18. Chemotherapy and radiation for prostate cancer.Translational andrology and urology · 2018
    Review
  19. Article
  20. Interleukin-4 induces a CD44Journal of cellular biochemistry · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 7 institutions in 1 country.

K L Mahon1] Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia [2] Cancer Research Division, Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW 2010, Australia [3] University of Sydney, Sydney, New South Wales 2050, Australia.
H-M LinCancer Research Division, Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW 2010, Australia.
L CastilloCancer Research Division, Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW 2010, Australia.
B Y LeeCancer Research Division, Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW 2010, Australia.
M Lee-NgSt Vincent's Centre for Applied Medical Research, Liverpool Street, Darlinghurst, NSW 2010, Australia.
M D ChatfieldMenzies School of Health Research, Darwin, NT, Australia.
K ChiamCancer Research Division, Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW 2010, Australia.
S N BreitSt Vincent's Centre for Applied Medical Research, Liverpool Street, Darlinghurst, NSW 2010, Australia.
D A BrownSt Vincent's Centre for Applied Medical Research, Liverpool Street, Darlinghurst, NSW 2010, Australia.
M P MolloyAustralian Proteome Analysis Facility, Macquarie University, NSW 2105, Australia.
G M MarxNorthern Haematology and Oncology Group, SAN Clinic, Wahroonga, NSW 2076, Australia.
N PavlakisRoyal North Shore Hospital, Pacific Highway, Sydney, NSW 2065, Australia.
M J Boyer1] Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia [2] University of Sydney, Sydney, New South Wales 2050, Australia.
M R Stockler1] Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia [2] University of Sydney, Sydney, New South Wales 2050, Australia.
R J DalySignalling Network Laboratory, Department of Biochemistry and Molecular Biology, School of Biomedical Sciences, Monash University, Clayton, VIC 3800, Australia.
S M HenshallCancer Research Division, Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW 2010, Australia.
L G Horvath1] Chris O'Brien Lifehouse, Missenden Road, Camperdown, NSW 2050, Australia [2] Cancer Research Division, Garvan Institute of Medical Research/The Kinghorn Cancer Centre, Darlinghurst, NSW 2010, Australia [3] University of Sydney, Sydney, New South Wales 2050, Australia.
Garvan Institute of Medical Research · AUChris O’Brien Lifehouse · AUMacquarie University · AUMenzies School of Health Research · AUMonash University · AURoyal North Shore Hospital · AUUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDocetaxel improves symptoms and survival in metastatic castration-resistant prostate cancer (CRPC). However, ∼50% of patients are chemoresistant. This study examined whether changes in cytokine levels predict for docetaxel resistance in vitro and in a clinical cohort.

methodsPC3 cells or their docetaxel-resistant subline (PC3Rx) were co-cultured with U937 monocytes, with and without docetaxel treatment, and cytokine levels were measured. The circulating levels of 28 cytokines were measured pre-/post cycle 1 of docetaxel from 55 men with CRPC, and compared with prostate-specific antigen (PSA) response.

resultsPC3Rx-U937 co-culture expressed more cytokines, chiefly markers of alternative macrophage differentiation, compared with PC3-U937 co-culture. Docetaxel treatment enhanced cytokine production by PC3Rx-U937 co-culture, while reducing cytokine levels in PC3-U937. In patients, changes in the levels of seven circulating cytokines (macrophage inhibitory cytokine 1 (MIC1), interleukin (IL)-1ra, IL-1β, IL-4, IL-6, IL-12 and IFNγ) after cycle 1 of docetaxel were associated with progressive disease (all P<0.05). The combination of changes in MIC1, IL-4 and IL-6 most strongly predicted PSA response (P=0.002).

conclusionsIn vitro studies suggest docetaxel resistance is mediated, at least in part, by cytokines induced by the interaction between the docetaxel-resistant tumour cells and macrophages. Early changes in circulating cytokine levels were associated with docetaxel resistance in CRPC patients. When considered together, these data suggest a significant role for the inflammatory response and macrophages in the development of docetaxel resistance in CRPC.

Indexed as

Drug Resistance, NeoplasmAgedAged, 80 and overAntineoplastic AgentsCell Line, TumorCoculture TechniquesCytokinesDocetaxelHumansKallikreinsMacrophagesMaleMiddle AgedProstate-Specific AntigenProstatic Neoplasms, Castration-ResistantTaxoidsAntineoplastic AgentsCytokinesDocetaxelKallikreinsKLK3 protein, humanProstate-Specific AntigenTaxoids

Identifiers

PMID25867259
PMCPMC4402456
OpenAlexW2016495957

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.